SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare advances on receiving final approval for Potassium Citrate ER Tablets

07 Aug 2014 Evaluate

Cadila Healthcare is currently trading at Rs. 1105.05, up by 9.95 points or 0.91 % from its previous closing of Rs. 1095.10 on the BSE.

The scrip opened at Rs. 1096.00 and has touched a high and low of Rs. 1121.15 and Rs. 1096.00 respectively. So far 2369 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1195.00 on 30-Jul-2014 and a 52 week low of Rs. 631.00 on 20-Aug-2013.

Last one week high and low of the scrip stood at Rs. 1168.10 and Rs. 1048.00 respectively. The current market cap of the company is Rs. 22870.41 crore.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 14.19 % and 11.01 % respectively.

Cadila Healthcare has received the final approval from the USFDA to market Potassium Citrate ER Tablets 5, 10 and 15 mEq, used in the prevention of kidney stones. As per IMS, the estimated sales in 2014 for Potassium Citrate ER Tablets stood at $131.7 million. The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare, previously known as Zydus Cadila, is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

1100.25 -4.10 (-0.37%)
15-Jun-2026 11:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1802.70
Dr. Reddys Lab 1286.00
Cipla 1385.45
Zydus Lifesciences 1100.25
Lupin 2282.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: